Shares of Mirati Therapeutics Inc. (NASDAQ:MRTX) doubled at their opening Friday morning and spiked to a 15-month high of $12.40 on word that the combination of the company's tyrosine kinase inhibitor (TKI), sitravatinib (MGCD-516), with Opdivo (nivolumab, Bristol-Myers Squibb Co.) showed three confirmed partial responses (PRs) in the first 11 evaluable patients with non-small-cell lung cancer (NSCLC) who had progressed following checkpoint therapy.